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A B S T R A C T   
Objective: To describe frequency of natalizumab related eosinophilia and clinical symptoms of eosinophilic dis-
ease in our monocentric cohort. 
Methods: Comparison of clinical characteristics of 115 natalizumab treated and 116 untreated RRMS patients and 
review of literature. 
Results: 38% of natalizumab treated patients had eosinophilia, which occurred significantly more frequently 
compared to untreated MS patients (3%, p-value<0.001). In symptomatic patients, mean eosinophil counts were 
significantly higher than in asymptomatic patients and symptoms developed within one year. 
Discussion: Eosinophilia is a side effect of natalizumab and mostly asymptomatic. However, few patients develop 
within one year after start of natalizumab an eosinophilic disease as severe side effect.   
1. Introduction 
Natalizumab (NTZ) is commonly used as treatment in relapsing 
remitting multiple sclerosis (RRMS). NTZ acts as a selective adhesion 
molecule antagonist, which binds very late antigen (VLA)-4 and inhibits 
the translocation of activated VLA-4-expressing leukocytes across the 
blood-brain barrier into the central nervous system. (Polman et al., 
2006; McCormack, 2013) Marked eosinophilia (defined as >1.0 G/l) 
was described in up to 10–19% of patients treated with NTZ. (Abbas 
et al., 2011; Florek et al., 2010) However, data on probability and fre-
quencies of clinical manifestations of hypereosinophilic syndromes with 
organ involvement under treatment with NTZ are sparse. So far, only 
two case reports of eosinophilic pneumonia and a single case report of 
each eosinophilic dermatitis and eosinophilic fasciitis during NTZ 
treatment have been described. (Curto et al., 2016; Yasuda et al., 2019; 
Bujold et al., 2014; André et al., 2010). 
The aim of our retrospective observational study was to describe the 
frequency of mild and marked eosinophilia and associated clinical 
symptoms with the help of our pharmacovigilance system in a large 
retrospective cohort of natalizumab treated RRMS patients since July 
2016. Moreover, our hypereosinophilic syndromes will be added to 
those published in the literature with the aim to identify parameters 
associated with clinical symptoms of natalizumab induced eosinophilia. 
2. Methods 
The retrospective study was approved by the local ethic committee 
(No 2017–01369, last amendment in November 2019). Patient data 
were extracted from the patient information system of our infusion ward 
using the search algorithm “natalizumab” or “Tysabri” and “Multiple 
sclerosis” or “Multiple sclerosis” alone. Hereby we identified 132 
consecutive NTZ treated MS patients in our center since July 2016. Af-
terwards all eosinophil counts of those patients were extracted from 
laboratory records leading to a final cohort of 115 patients with at least 
one measurement of eosinophil granulocytes in peripheral blood and in 
total 621 measurements since July 2016. In our center, we perform an 
analysis of whole blood count, ALAT, gamma-GT, sodium, potassium, 
creatinine and C-reactive protein in every patient on natalizumab before 
initiation of therapy, after 4 months and from there on every 6 months. 
However, 17 patients had no measurement of eosinophil counts in our 
center (as they were performed at the general practitioner) and were 
therefore excluded. Patients with mild eosinophilia (defined as eosino-
phil granulocytes >0.4 G/l, but <1 G/l) and marked eosinophilia 
(defined as eosinophil granulocytes >1 G/l(Florek et al., 2010)) were 
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subsequently identified in this cohort. Additionally, we identified 116 
untreated RRMS patients since July 2016 at least one measurement of 
eosinophil granulocytes in peripheral blood, analyzed the laboratory 
records and compared those with the NTZ treated MS patients. Patient 
records of these cases were then manually checked by neuro-
immunologic consultants (RH, CF, LD) for clinical symptoms during 
blood eosinophilia. 
2.1. Literature review 
PubMed database was searched twice by (CF, RH, LD) using the 
search terms “eosinophilic/eosinophilia natalizumab” and “eosino-
philic/eosinophilia Tysabri” (date of last PubMed search 29.10.2020). 
Hereby 9 articles (Abbas et al., 2011; Florek et al., 2010; Curto et al., 
2016; Yasuda et al., 2019; Bujold et al., 2014; André et al., 2010; Rocher 
et al., 2010; Mihalova et al., 2015; Beales, 2019) dealing with blood 
eosinophilia with and without clinical symptoms during natalizumab 
treatment were identified. We compared the data of those studies to our 
own data and analyzed all reported cases of asymptomatic and symp-
tomatic eosinophilia in NTZ treated patients. 
2.2. Statistic 
Continuous variables were presented as mean and 95% confidence 
interval (95%CI) (where applicable) or as median and 25th/75th 
percentile and compared using the non-parametric Mann-Whitney U test 
or the Kruskal-Wallis-Test in independent samples. Categorical variables 
were reported as frequencies and compared with Chi2 test (where 
applicable) or the Fisher-Yates (exact Fisher) test. 
3. Results 
3.1. Untreated compared to natalizumab treated MS patients 
We identified in our institution since July 2016 a cohort of 115 
natalizumab (NTZ) treated RRMS patients and 116 untreated RRMS 
patients with at least one measurement of eosinophil counts in periph-
eral blood (Fig. 1). Mean age and sex distribution of untreated and NTZ 
treated RRMS patients were evenly distributed (age NTZ: 41.9 years 
(95%CI 39.4–44.4 years) vs age untreated 39.4 years (95%CI 37.3–41.4 
years), p-value = 0.30; female sex NTZ: 85/115 vs female sex untreated: 
77/116, p-value = 0.29). 112/116 untreated RRMS patients (97%) had 
normal eosinophil counts and the remaining 4/116 (3%) showed mild 
eosinophilia (Table 1). Eosinophilia occurred significant less frequently 
in untreated RRMS patients compared to NTZ treated RRMS patients 
(mild eosinophilia: 37/115 patients (32%); marked eosinophilia 7/115 
patients (6%); p-value<0.001, Table 1, Fig. 1). 
3.2. Natalizumab induced eosinophilia 
Patient records of all patients with blood eosinophilia were manually 
checked by neuroimmunologic consultants (RH, CF, LD) for clinical 
symptoms during blood eosinophilia and other possible reasons for 
blood eosinophilia like allergies, helminthiasis, or other diseases. Mean 
observed NTZ treatment duration was 61.2 months (25th-75th percen-
tile 31–88 months). Any eosinophilia occurred in 44/115 NTZ treated 
RRMS patients and age distribution did not differ in patient groups 
classified by presence and severity of eosinophilia (Kruskal-Wallis-test p- 
value = 0.402, Table 2). Regarding sex distribution, a trend towards a 
higher percentage of female sex in NTZ treated RRMS patients with 
eosinophilia was observed (p-value = 0.045). Median time to first 
eosinophilia in all 44 NTZ treated patients was 49.5 months (25th-75th 
percentile 24.3–76.8 months), whereas median time to maximal eosin-
ophilia was 53 months (25th-75th percentile 28.8–78). In those NTZ 
treated RRMS patients with eosinophilia, median time until 1st blood 
eosinophilia as well as median time until maximal eosinophil count were 
not shorter in patients with marked eosinophilia compared to patients 
with mild eosinophilia (1st blood eosinophilia, p-value = 0.148; 
maximal eosinophilia: p-value = 0.205; Table 2). As mentioned above, 
in our center we perform an analysis of whole blood count, ALAT, 
gamma-GT, sodium, potassium, creatinine and C-reactive protein in 
every patient on natalizumab before initiation of therapy, after 4 months 
and from there on every 6 months. If a patient displays abnormal values 
at these checks, we usually perform more regular laboratory exams. 
Except one patient (1/44) detailed below, all other patients with any 
eosinophilia under treatment with NTZ remained asymptomatic. 
3.3. Case report of the patient with clinical symptoms of natalizumab 
induced eosinophilia 
Our symptomatic patient is a 39-year-old nonsmoking woman with 
RRMS diagnosed in August 2018. Oligoclonal Bands type 2 and cerebral 
magnetic resonance imaging (MRI) scans supported the diagnosis of a 
RRMS (Fig. 2) and we found no alternative diagnosis. Treatment with 
natalizumab was started in August 2018. In October 2018, after 2 in-
fusions of natalizumab, she developed fever and a productive cough. Her 
general practitioner started an antibiotic treatment with amoxicillin/ 
clavulanic acid and inhaled steroids, as the X-ray of the chest showed 
reticular opacities in the upper left side of the lung (X-ray not shown). In 
December 2018 (after 4 infusions of natalizumab) she presented in our 
neuroimmunologic outpatient department for the regular control and 
she complained about chronic coughing. She reported no arthralgia, no 
asthma or oral ulcers. In the blood samples a marked eosinophilia 
(maximal value 2.89 G/L, range 0.1–2.89 G/l, range of normal 0.02–0.4 
G/L, n = 9; maximal value of leucocytes 20.8 G/l, range 7.17–20.8 G/l, 
range of normal 3.00–10.5 G/l, n = 11), with slightly elevated C-reactive 
protein (CRP) (12 mg/l) was found. A pulmonary computed tomography 
(CT) scan showed multiple lung masses with aerobronchograms and a 
lesion in the upper right lobe (Fig. 3A). Tests for autoimmune diseases, 
connective tissue diseases, and vasculitis showed an anti-neutrophil 
cytoplasmic antibodies (ANCA) titer of 1:320 (range < 1:80) with 
elevated PR3-ANCA (95.1 IU/ml, range < 5 IU/ml); whereas antinuclear 
antibodies, anti-DNA, anti-Sm, anti-ribonucleoprotein, anti-Ro, anti-La, 
anti-centromere, anti-SCL 70, anti-Jo1, anti-citrullinated peptide, and 
rheumatoid factor remained negative. The pulmonary CT scan showed 
no lymphadenopathy, and in the cranial MRI there were no signs of an 
infectious process. In the follow-up pulmonary CT scan, after re- 
exposition to natalizumab in March 2019, a worsening with extensive 
bilateral consolidations could be seen, but still no signs of lymphade-
nopathy or granuloma (Fig. 3B). The bronchoscopy did not demonstrate 
endobronchial lesions, whereas the bronchoalveolar lavage and the bi-
opsy showed a lymphohistiocytic inflammatory cell infiltrate with 
eosinophilic granulocytes, but no acute purulent inflammation. Cultures 
for bacteria, mycobacteria, fungi, and studies for parasites and virus 
remained negative. The resulting diagnosis was “pulmonary eosino-
philia associated with natalizumab treatment”. Despite the increased 
PR3-ANCA values, we found no clinical, laboratory or radiological sign 
for an eosinophilic granulomatosis with polyangiitis, granulomatosis 
with polyangiitis, microscopic polyangiitis or anti-glomerular basement 
membrane autoantibody disease. We found no signs of a drug-induced 
ANCA-associated vasculitis, where usually MPO-ANCA and not PR3- 
ANCA are encountered and NTZ has not been described as a possible 
offending agent (Pendergraft 3rd and Niles, 2014). We found no corre-
lation of elevated ANCA values to natalizumab in literature. We stopped 
the therapy with natalizumab and started systemic corticosteroids (1 
mg/kg body weight) and subsequently Ocrelizumab in December 2019. 
At the last follow-up visit in January 2020, the patient was asymptom-
atic, the laboratory examination showed a normal eosinophilic count 
and the pulmonary CT scan showed an almost complete resolution of the 
pulmonary infiltrates (Fig. 3C). 
L. Diem et al.                                                                                                                                                                                                                                    
Journal of Neuroimmunology 353 (2021) 577505
3
Fig. 1. Eosinophil counts in peripheral blood of untreated and natalizumab treated RRMS patients. Abbreviations: RRMS: relapsing remitting multiple sclerosis; G/l: 
giga/l; arrows denote patients with marked eosinophilia. 
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3.4. Review of the literature 
Reviewing the scientific literature leads to identification of 4 addi-
tional case reports of natalizumab treated RRMS patients with symp-
tomatic eosinophilia (Curto et al., 2016; Yasuda et al., 2019; Bujold 
et al., 2014; André et al., 2010) and 3 cases with asymptomatic marked 
eosinophilia with cell counts >1 G/l (Abbas et al., 2011). In our single 
center cohort we found 1 case of symptomatic eosinophilia, 6 cases of 
asymptomatic marked eosinophilia and 37 cases of mild eosinophilia 
(which all remained asymptomatic) of in total 115 NTZ treated RRMS 
patients with at least one eosinophil count since July 2016. So far, there 
were no NTZ treated patients with mild eosinophilia described in 
literature. 
This leads to a total case count of 51 NTZ treated RRMS patients with 
eosinophilia (consisting of our own 44 patients and 7 patients described 
in literature). Eosinophil counts of all 51 symptomatic and asymptom-
atic patients ranged from 0.41 G/l to 5.52 G/l and were in mean 1.1 G/l 
(95%CI 0.79–1.41). Mean age of all patients was 39.1 years (95%CI 
34.1–42.1 years). The 46 asymptomatic patients had a mean eosinophil 
count of 0.92 G/l (95%CI 0.65–1.18 G/l), whereas the 5 symptomatic 
patients had a significantly higher mean eosinophil count of 2.75 G/l 
(95%CI 0.71–4.79 G/l, p-value<0.001). Three of five (60%) symptom-
atic patients were female, whereas 26 of 46 (57%) asymptomatic pa-
tients were female (p-value = 0.63). In symptomatic patients, symptoms 
were pneumonia (n = 3 (1,7 and our case)), fasciitis (n = 1 (Rocher et al., 
2010)) and dermatitis (n = 1 (Mihalova et al., 2015)). Eosinophilia in 
symptomatic and asymptomatic patients started between 1 month and 
114 months after initiation of NTZ (median 36 months, 25th-75th 
percentile 12–68 months). Eosinophilic disease started between 1 and 
12 months after initiation of NTZ (median 2 months; 25th75th 1–9 
months), whereas asymptomatic eosinophilia was found significantly 
later between 1 and 114 months after initiation of NTZ (median 47 
months; 25th-75th percentile 19–74.3 months, p value = 0.004). 
4. Discussion 
Natalizumab is commonly used as treatment in RRMS. It is 
commonly well tolerated, but a rarely described adverse effect of 
Natalizumab seems to be a symptomatic or asymptomatic eosinophilia. 
(Abbas et al., 2011; Curto et al., 2016; Yasuda et al., 2019; Bujold et al., 
2014; André et al., 2010; Rocher et al., 2010). 
In the literature, eosinophilia is described in 10–19% of patients 
under treatment with natalizumab (Abbas et al., 2011; Florek et al., 
2010). We found no data of cohort analyses regarding the frequency of 
symptomatic eosinophilia under treatment with natalizumab, hence our 
work delivers the first such data set so far. In our cohort of 132 RRMS 
patients under treatment with natalizumab since July 2016, we had at 
least one eosinophil counts of 115 patients (87% of all patients). Of those 
115 patients, 7 patients had a marked eosinophilia (6% of all patients 
with eosinophil counts) and only one of those (0.9% of all patients with 
eosinophil counts) was symptomatic. Another 37 treated patients (32%) 
showed mild eosinophilia, which all remained asymptomatic. In 
conclusion, in our single center cohort, 44 of 115 natalizumab treated 
RRMS (38%) patients showed an eosinophilia, which is higher than the 
reported frequency in the literature and remained in 99% of cases 
without clinical symptoms. Some studies suggest that natalizumab may 
cause peripheral hypereosinophilia in a subset of patients. The obser-
vation of these subgroups shows a close relationship between natalizu-
mab and eosinophilia, which emerges a few weeks after treatment 
initiation, disappears after drug discontinuation, and reappears after 
natalizumab re-exposition. (Abbas et al., 2011; Rocher et al., 2010) The 
risk factors and exact mechanisms leading to marked hypereosinophilia 
under natalizumab treatment remain unknown, an association with Th2 
immune responses was discussed. (Abbas et al., 2011). 
In our cohort, we first found eosinophilia in natalizumab treated 
patients after a median treatment duration of 49.5 months (25th-75th 
Table 1 
Eosinophilia in NTZ treated and untreated RRMS patients. Abbreviation: NTZ: 
natalizumab; RRMS: relapsing remitting multiple sclerosis.  
Eosinophilia  
No Mild Marked p-value 
No treatment 112 4 0  
NTZ 71 37 7 <0.001  
Table 2 
Baseline characteristics of NTZ treated patients without, with mild and with 
marked eosinophilia.  
Baseline characteristics of NTZ treated patients without eosinophilia  
Mean 95% CI Median 25th/75th 
percentile 
n 
Age all (years) 39.5 36.9–42.2   71 
Age female (years) 38.7 35.5–42   53 
Age male (years) 42 36.9–47.1   18 
Observed treatment all 
(months)   
60 31/88 71 
Observed treatment f 
(months)   
61 34.5/88.5 53 
Observed treatment m 
(months)   
53 18.5/90.5 18 
Baseline characteristics of NTZ treated patients with mild eosinophilia 
Age all (years) 39.9 36.2–43.6   37 
Age female (years) 37.1 31.5–42.7   19 
Age male (years) 42.8 37.5–48.2   18 
Observed treatment all 
(months)   
62 42/88.5 37 
Observed treatment 
female (months)   
63 42/85 19 
Observed treatment 
male (months)   
61.5 47.3/91.8 18 
NTZ treatment to eos 
all (months)   
54 25.5/78 37 
NTZ treatment to eos 
female (months)   
54 19/78 19 
NTZ treatment to eos 
male (months)   
53 29/82.5 18 
NTZ treatment to max 
eos all (months)   
56 36/79 37 
NTZ treatment to max 
eos female (months)   
56 27/78 19 
NTZ treatment to max 
eos male (months)   
53 29/82.5 18 
Baseline characteristics of NTZ treated patients with marked eosinophilia 
Age all (years) 34.4 25.2–43.7   7 
Age female (years) 38.8 28.8–48.8   5 
Age male (years) 23.5 n/a   2 
Observed treatment all 
(months)   
47 24/80 7 
Observed treatment 
female (months)   
24 16/103 5 
Observed treatment 
male (months)   
50 n/a 2 
NTZ treatment to eos 
all (months)   
30 2/58 7 
NTZ treatment to eos 
female (months)   
19 1.5/74.5 5 
NTZ treatment to eos 
male (months)   
31.5 n/a 2 
NTZ treatment to max 
eos all (months)   
34 16/63 7 
NTZ treatment to max 
female (months)   
22 12/86 5 
NTZ treatment to max 
male (months)   
36.5 n/a 2 
Abbreviations: 95% CI: 95% confidence interval; eos: eosinophilia; f: female; m: 
male; max: maximal; n/a: not applicable; NTZ: natalizumab. 
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percentile: 24.3–76.8 months), whereas median time to maximal 
eosinophilia was 53 months (25th-75th percentile, 28.8–78 months). 
However, severity of eosinophilia was related to clinical symptoms, as 
patients with eosinophilic disease had significant higher eosinophil 
counts than those who remained asymptomatic. Further, a symptomatic 
eosinophilia developed in all documented cases within one year of NTZ 
treatment and the lung was most often affected highlighting the po-
tential threat of NTZ induced eosinophilic disease. 
The main limitation of our study is the retrospective nature and 
single center design. However, as eosinophil counts were available in 
more than 80% of the identified consecutive natalizumab treated MS 
patients, our cohort can be regarded as a representative sample for 
Caucasian RRMS patients. As we perform an analysis of whole blood 
count, ALAT, gamma-GT, sodium, potassium, creatinine and C-reactive 
protein in every patient on natalizumab before initiation of therapy, 
after 4 months and from there on every 6 months, a selection bias is 
unlikely. Another limitation are the positive PR3-ANCA values of our 
patient with the eosinophilic pneumonia, where we cannot rule out a 
causal relation. However, this has not been described in literature so far. 
In conclusion, our work sheds light on a seemingly rare and so far 
little discussed aspect of treatment with natalizumab. Even though the 
eosinophilia seems to become rarely symptomatic, it is highly relevant 
to spread the knowledge of this adverse effect of natalizumab, as nata-
lizumab has to be stopped to treat this potentially severe condition. 
Further studies on drug safety in real life settings are warranted to better 
describe drug associated toxicity and adverse effects. 
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